SCHEMBL360314

SCHEMBL360314

O=CC(=O)c1ccc(F)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.58
ALDH1A1 P00352 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
TNFRSF1A P19438 1/20 0.57
CES2 O00748 1/20 0.56
CES1 P23141 1/20 0.56
MAPT P10636 2/20 0.55
CYP1A2 P05177 1/20 0.53
CYP2C19 P33261 1/20 0.53
CA1 P00915 2/20 0.52
CA2 P00918 2/20 0.52
BCL2L1 Q07817 1/20 0.48
BAD Q92934 1/20 0.48
BRAF P15056 1/20 0.47
RAB9A P51151 2/20 0.46
PTPN1 P18031 1/20 0.46
NPC1 O15118 1/20 0.46
MAOA P21397 1/20 0.46
MAOB P27338 1/20 0.46
CYP1A1 P04798 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL1360217 0.98 MAPK1 (0.56) MAPK1ALDH1A1TDP1TNFRSF1ACES2
SCHEMBL10991995 0.98 MAPK1 (0.56) MAPK1ALDH1A1TDP1TNFRSF1ACES2
SCHEMBL13270530 0.88 TNFRSF1A (0.47) MAPK1ALDH1A1TDP1TNFRSF1ACES2
SCHEMBL222221 0.87 ALDH1A1 (0.74) MAPK1ALDH1A1TDP1TNFRSF1AMAPT
Water SCHEMBL11592745 0.84 ALDH1A1 (0.70) MAPK1ALDH1A1TDP1TNFRSF1AMAPT
Water SCHEMBL11592742 0.84 ALDH1A1 (0.70) MAPK1ALDH1A1TDP1TNFRSF1AMAPT
SCHEMBL8923089 0.83 MAPT (0.46) MAPK1ALDH1A1TDP1TNFRSF1ACES2
SCHEMBL6989990 0.82 TNFRSF1A (0.72) MAPK1ALDH1A1TDP1TNFRSF1ACES2
SCHEMBL6989989 0.82 TNFRSF1A (0.72) MAPK1ALDH1A1TDP1TNFRSF1ACES2
SCHEMBL4214525 0.80 TNFRSF1A (0.57) MAPK1TNFRSF1ACES2CES1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115894870-B Polymer and polymer nanoparticle of benzobisquinoxaline receptor for photothermal therapy, and preparation and application thereof 华南理工大学 2024-06-25 CN claimed
CN-115894870-A Polymer and polymer nanoparticle of benzo-bis-quinoxaline receptor for photothermal therapy, and preparation and application thereof 华南理工大学 2023-04-04 CN claimed
US-20220290106-A1 Method for Promoting Cell Proliferation, and Method for Preparing Cell Cluster OSAKA UNIVERSITY (JP) 2022-09-15 US claimed
EP-3998333-A1 METHOD FOR PROMOTING CELL PROLIFERATION, AND METHOD FOR PREPARING CELL CLUSTER Osaka University (JP) 2022-05-18 EP claimed
WO-2021006346-A1 METHOD FOR PROMOTING CELL PROLIFERATION, AND METHOD FOR PREPARING CELL CLUSTER 国立大学法人大阪大学 2021-01-14 WO claimed
US-20130189245-A1 METHOD FOR PRODUCING TOXOIDS USING ALPHA-DICARBONYL COMPOUNDS THE SECRETARY OF STATE FOR DEFENCE (GB) 2013-07-25 US claimed
EP-2593132-A2 METHOD FOR PRODUCING TOXOIDS USING ALPHA - DICARBONYL COMPOUNDS& xA; The Secretary of State for Defence (GB) 2013-05-22 EP claimed
CN-103079590-A Method for producing toxoids using alpha - dicarbonyl compounds SECR DEFENCE 2013-05-01 CN claimed
WO-2012007728-A2 TOXOIDING METHOD THE SECRETARY OF STATE FOR DEFENCE (GB) 2012-01-19 WO claimed
US-6130331-A Chemical synthesis of a chiral 1,4-oxazin-2-one MERCK SHARP & DOHME LTD. (GB) 2000-10-10 US claimed
US-5610016-A REACTING A GLYOXAL DERIVATIVE, CHEMILUMINESCENCE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1997-03-11 US claimed
EP-0675360-A2 Method for measuring adenyl group containing substances using heteropoly acid MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1995-10-04 EP claimed
EP-4598923-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS The Regents of the University of California (US) 2025-08-13 EP disclosed
WO-2024210572-A1 NOVEL IMIDAZOLE DERIVATIVE AND USE THEREOF 주식회사 펠레메드 2024-10-10 WO disclosed
US-12054472-B2 1,2,4-triazine-4-amine derivatives NXERA PHARMA UK LIMITED (GB) 2024-08-06 US disclosed
CN-115894870-B Polymer and polymer nanoparticle of benzobisquinoxaline receptor for photothermal therapy, and preparation and application thereof 华南理工大学 2024-06-25 CN disclosed
US-4536517-A ANTIDIABETIC, ANTILIPEMIC AGENTS AMERICAN CYANAMID COMPANY (US) 1985-08-20 US disclosed
EP-0137333-A2 Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase ALCON LABORATORIES, INC. (US) 1985-04-17 EP disclosed
US-4159375-A 6- AND 7-Aryl-1,2,4-triazolo[4,3-b]-1,2,4-triazines AMERICAN CYANAMID COMPANY (US) 1979-06-26 US disclosed
US-4046763-A INTERMEDIATE FOR ULTRAVIOLET LIGHT ABSORBERS MCNEIL LABORATORIES, INCORPORATED (US) 1977-09-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12054472-B2 1,2,4-triazine-4-amine derivatives ADORA2A, ADORA2B, ADORA1 MAPK1 2655/4885ALDH1A1 251/4885TDP1 2273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.